Navigation Links
The Counter Effect Of Alzheimer's Drug

Quetiapine, a drug used to treat agitation in patients with Alzheimer's or dementia, may actually worsen cognitive decline say researchers based on findings of a recent study .//

For the study 80 nursing home patients were observed . Twenty-six of the patients received quetiapine (an antipsychotic also known as Seroquel), 25 received rivastigmine (a cholinesterase inhibitor also known as Exelon), and 29 received a placebo. Patients were monitored for agitation and cognition levels at baseline, six weeks, and 26 weeks.Neither of the groups showed any significant improvement in agitation after six or 26 weeks compared to the placebo group. It was also observed that those taking quetiapine showed a significant cognitive decline.

Thus researchers say though quetiapine has been regarded as one of the safer antipsychotics, their study indicates that quetiapine should not be used as an alternative treatment to other antipsychotics such as risperidone (Risperdal) or olanzapine (Zyprexa or Zydis) in people with dementia as it seemed of no benefit in patients with dementia and agitation in institutional care but was rather associated with greater cognitive decline .
'"/>




Page: 1

Related medicine news :

1. Over-The-Counter Drugs May Prevent Alzheimers
2. Drug In Asthma inhaler Found To Counteract Benefits
3. The Risks Involved In Purchase Of Over The Counter Medications
4. Free Condom Counters For Border Security Force Cadres
5. Aspirin Might Counter Side Effects of Cox-2 Painkillers
6. Compound In Grapes And Red Wine To Counter Alzheimers Disease
7. Proper Diet Can Counter Macular Degeneration
8. Counter study: cholesterol drugs no good in preventing colon cancer
9. Need For Smarter Ways To Identify Fake Drugs & Internet Counterfeiting: WHO
10. Negative Effects of Asthma Can Be Countered With Personality changes
11. Counterfeiter Packs Health Problems: Study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... enhanced Pepper Flow promotional review platform at the Promotional Review Committee Compliance ... capabilities help marketers streamline the medical, legal, and regulatory review (MLR) process ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: